CYRX vs SYNC.L
CYRX: Cryoport is the leading provider of end-to-end temperature-controlled supply chain solutions specifically built for cell and gene therapies, from preclinical development through global commercialization. SYNC.L: A London-listed investment firm that creates and builds pioneering life science companies, with a specialized focus on advanced therapies and oncology.
Side-by-side fundamentals
| Metric | CYRX | SYNC.L | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $15.25 | £1.07 | |
| Market cap as of 2026-08-06 | $769M | n/a | |
| P/E as of 2026-08-06 | 10.09 | n/a | |
| Net margin as of 2026-08-06 | +41.6% | n/a | |
| Gross margin as of 2026-08-06 | +47.2% | n/a | |
| Operating margin as of 2026-08-06 | -21.4% | n/a | |
| ROE as of 2026-08-06 | +15.0% | n/a | |
| ROA as of 2026-08-06 | +9.9% | n/a | |
| Debt / equity as of 2026-08-06 | 0.38 | n/a | |
| Revenue growth (YoY) as of 2026-08-06 | -14.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -9.4% | n/a | |
| Beta as of 2026-08-06 | 1.97 | n/a | |
| 1-year return as of 2026-08-05 close | +126.3% | +10.7% | CYRX higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.